Compare BFRG & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFRG | TCRT |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 7.8M |
| IPO Year | 2022 | 2025 |
| Metric | BFRG | TCRT |
|---|---|---|
| Price | $0.37 | $1.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 148.1K | ★ 290.2K |
| Earning Date | 11-13-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.88 | 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | $116,670.00 | ★ $15,900,000.00 |
| Revenue This Year | $568.55 | N/A |
| Revenue Next Year | $573.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.49 | N/A |
| 52 Week Low | $0.39 | $0.72 |
| 52 Week High | $1.96 | $4.50 |
| Indicator | BFRG | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 47.70 |
| Support Level | N/A | $1.61 |
| Resistance Level | $0.69 | $1.82 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 2.00 | 47.44 |
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.